Herriot Tabuteau, MD

CEO
Axsome Therapeutics Inc. New York, NY, USA

Poster(s):

• (56) Efficacy and Safety of AXS-05 in Alzheimer's Disease Agitation: Results From ACCORD-2, a Phase 3 Randomized Withdrawal Double-Blind Placebo-Controlled Study
  Wednesday, October 29, 2025

• (58) Efficacy and Safety of Symbravo® (MoSEICTM meloxicam and rizatriptan) in Participants With Migraine Experiencing an Inadequate Response to Oral CGRP Inhibitors: Topline Results From the EMERGE Trial
  Wednesday, October 29, 2025